Phase 2 data expected in 2H 2026 - - KPL-387 Phase 1 single ascending dose data support profile for monthly dosing - LONDON, ...

GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving ...

Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® ...

YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne. The stock jumped 42%, to $5.20 ...

Tessa Romero, JPMorgan: Inquired about the rapid enrollment pace in Phase 3 trials. Chief Medical Officer ... expenses driven by accelerated clinical trial activity. Management maintained a ...

Bayer Pharmaceutical has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced promising results from its Phase 2 trial of NBI-1117568, a first-in ...

Management outlined plans to propose a Phase 3 clinical trial for enobosarm, targeting older patients with obesity or overweight conditions. The primary endpoint will focus on physical function ...